Clinical trials: Digestive Organs--Cancer
Rectal Cancer Stage I
Endoscopic (EID) Versus Surgical (TAMIS) Local Excision for Early Stage Rectal Cancer
In this clinical trial, we compare the endoscopic technique, endoscopic intermuscular dissection (EID), with the surgical technique, transanal minimally invasive surgery (TAMIS) for the treatment of early stage rectal cancer.
- Trial name
- ENSURE (NCT07846046)
- Testing
- Endoscopic Intermuscular Dissection (EID), Transanal Minimally Invasive Surgery (TAMIS)
- Where
- 19 sites in Netherlands
- Volunteers
- 246 people
- Sponsor
- Amsterdam UMC, location VUmc
Rectal Cancer
The Development of a Patient Reported Outcomes Measure Committed to the Watch-and-wait Program for Rectal Cancer
The purpose of this study to develop an international tool that can be used to assess burden of disease in patients enrolled in the W\&W program for rectal cancer
- Trial name
- NCT05040646
- Testing
- Delphi exercise
- Where
- Netherlands
- Volunteers
- 80 people
- Sponsor
- Maastricht University Medical Center
Cancer of Oropharynx, Cancer of Nasopharynx
Dysphagia Assessment After Swallowing Sparing RadioTherapy
To prospectively assess post-radiation late dysphagia by using MDADI questionnaire (deglutition-related quality of life) and objective instrumental assessment by means of Fiberoptic Endoscopic Evaluation of Swallowing (FEES) and…
- Trial name
- DASRT (NCT03448341)
- Where
- Italy
- Volunteers
- 74 people
- Sponsor
- Azienda Ospedaliero, Universitaria Pisana
Sigmoid Cancer, Sigmoid Colon Cancer
Sigmoid Colon Organ Motion in Radiotherapy
Radiotherapy is used in cancer treatment to eradicate microscopic cancer cells to lower the risk of recurrence. The radiotherapy plan must account for organ movement inside the body to ascertain adequate dose is delivered to the…
- Trial name
- NCT03259828
- Testing
- Adjuvant image-guided radiotherapy
- Where
- Taiwan
- Volunteers
- 4 people
- Sponsor
- National Cheng-Kung University Hospital
Rectal Cancer
Implementation of a Tumor Response Assessment Program Integrating the Shared Medical Decision Into the Organ Preservation Strategy for Rectal Cancer Patients
The adoption of total mesorectal excision (TME) has standardized rectal cancer surgery and improved oncological outcomes. In locally advanced rectal cancer, neoadjuvant radio chemotherapy (NACRT) has further improved oncological…
- Trial name
- EVAREC (NCT06740357)
- Testing
- Tumor response monitoring program, Standard evaluation of tumor response, Shared decision-making
- Where
- France
- Volunteers
- 270 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Rectal Cancer, Organ-Space Surgical Site Infection
Concordance Between Monitoring Systems for Organ/Space Surgical Site Infections in Rectal Surgery
The Catalan Cancer Plan (CCP) undertakes periodic audits of cancer treatment outcomes, including organ/space surgical site infections (O/S-SSI) rates, while the Catalan Healthcare-associated Infections Surveillance Programme…
- Trial name
- NCT06104579
- Testing
- Person-level linkage of both databases looking for concordance in the diagnosis of organ-space surgical site infection
- Where
- Spain
- Volunteers
- 11,367 people
- Sponsor
- Hospital de Granollers
Malignant Neoplasms of Digestive Organs
CART Therapy in Digestive System Tumors
Chimeric Antigen Receptor T Cells (CART) Therapy in GUYC2C postive Digestive system tumors, include colorectal cancer, gastric cancer, liver cancer, pancreatic cancer, adenocarcinoma of esophagus, cancer of the esophagogastric…
- Trial name
- NCT04780529
- Testing
- gucy2c cart cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Innovative Cellular Therapeutics Co., Ltd.
Colon Cancer
Colon Cancer Prognosis After Radical Surgery
1. Radical surgery. It is supposed to improve prognosis of colon cancer. A surrogate measure of achievement of radical surgery is the number of lymph nodes removed with the specimen. 2. Markers.
- Trial name
- NCT00963352
- Where
- 2 sites in Norway
- Volunteers
- 300 people
- Sponsor
- Haraldsplass Deaconess Hospital
Malignant Neoplasms of Digestive Organs, Colorectal Cancer
Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer
The goal of this clinical research study is to learn if durvalumab and trametinib can help to control microsatellite stable (MSS) colorectal cancer. The safety of these drugs will also be studied.
- Conditions
- Malignant Neoplasms of Digestive Organs, Colorectal Cancer, Colon Cancer
- Trial name
- NCT03428126
- Testing
- Durvalumab, Trametinib
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer of the Breast, Cancer of Stomach
Vocorder Device Validation in Clinical Settings - Continuous Monitoring of Individuals (Vocorder Clinical Validation-VCV)
This is performed under Vocorder project that is Co-Funded by the European Union. (Grant Agreement 101115442 VOCORDER HORIZON EIC-2022-PATHFINDERCHALLENGE-01).
- Conditions
- Cancer of the Breast, Cancer of Stomach, Colon Cancer, Lung Cancers
- Trial name
- VCV (NCT06711939)
- Where
- Greece
- Volunteers
- 515 people, healthy volunteers welcome
- Sponsor
- Mitera Hospital
Rectal Adenocarcinoma, Non Metastatic
A Global, Integrated, Personalized, Stage-related, Multimodal Therapeutic Approach for Rectal Adenocarcinoma Based on Organ Sparing and Mininvasivity
A phase II, single-center, non-profit, interventional study on patients affected by rectal adenocarcinoma. Patients will be stratified into three groups based on pre-treatment clinical stage.
- Trial name
- INTERPRETE (NCT06952101)
- Testing
- Sparing Approach, experimental chemoradiotherapy, Standard Chemotherapy
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Esophageal Cancer, Chemoradiation
Organ Motion and Early Tumor Response Measurement
To quantify motion based variation of the target volume of the primary tumor over the course of chemoradiotherapy in esophageal cancer patients, and to use this information to calculate appropriate PTV (planning target volume)…
- Trial name
- NCT02139488
- Testing
- Fiducial markers, Fiducial markers, Pet and MRI
- Where
- Netherlands
- Volunteers
- 80 people
- Sponsor
- The Netherlands Cancer Institute
Anal Cancer, Colorectal Cancer
Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer
RATIONALE: Octreotide may be effective in preventing or controlling diarrhea in patients who are undergoing chemoradiotherapy for anal or rectal cancer. It is not yet known whether octreotide is effective in treating diarrhea.
- Conditions
- Anal Cancer, Colorectal Cancer, Drug/Agent Toxicity by Tissue/Organ, Radiation Enteritis
- Trial name
- NCT00075868
- Testing
- octreotide acetate
- Where
- 112 sites in United States
- Volunteers
- 233 people
- Sponsor
- Radiation Therapy Oncology Group
Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Female Genital Organs
Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies
The goal of this clinical research study is to find the highest tolerable dose of the combination of alisertib and TAK-228 that can be given to participants with advanced solid tumors that are associated with HPV.
- Conditions
- Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Lip Oral Cavity and Pharynx, Malignant Neoplasms of Male Genital Organs
- Trial name
- NCT02812056
- Testing
- Alisertib, TAK-228
- Sponsor
- M.D. Anderson Cancer Center
Esophageal Squamous Cell Carcinoma
Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC
To observe the 1-year disease-free survival rate （1-year PFS） of patients with resectable esophageal squamous cell carcinoma who received neoadjuvant chemoradiotherapy combined with camrelizumab and achieved clinical complete…
- Trial name
- WATCHER (NCT05507411)
- Testing
- Neoadjuvant Radiotherapy, Neoadjuvant Chemotherapy, Immunotherapy
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Zhejiang Cancer Hospital
Rectal Cancer
Organ Preservation First Strategy and Intentional Watch and Wait for MRI Defined Low-risk Rectal Cancer
The goal of this clinical trial is to test the safety and efficacy of local excision (LE) or non-operative management (NOM) in patients with MRI defined low-risk rectal cancer following neoadjuvant intensity modulated…
- Trial name
- NCT06209099
- Testing
- Nonoperative Management (NOM), Local Excision (LE), Total Mesorectal Excision (TME)
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Peking University Cancer Hospital & Institute
Rectal Cancer
A Multicenter Single-arm P2 to Evaluate Safety and Efficacy of the Total Neoadjuvant Therapy for cT2 Rectal Cancer
A multicenter single-arm phase 2 study to evaluate safety and efficacy of the total neoadjuvant therapy of short course radiation therapy followed by neoadjuvant oxaliplatin/fluorouracil-based chemotherapy (CAPOX) for cT2 rectal…
- Trial name
- AMBITION (NCT05939661)
- Testing
- Radiation, Chemotherapy, Surgery
- Where
- 2 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Osaka University
Liver Failure, Liver Diseases
Everolimus in de Novo Liver Transplantation: a Multicentre Randomized Study
Safety and Efficacy of Everolimus in adult de novo liver transplant recipients.
- Conditions
- Liver Failure, Liver Diseases, Liver Cirrhosis, Liver Neoplasms
- Trial name
- EPOCAL (NCT01423708)
- Testing
- Everolimus
- Where
- 7 sites in Italy
- Volunteers
- 117 people
- Sponsor
- Azienda Ospedaliera di Padova
Carcinoma, Carcinoma, Hepatocellular
SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA
The goal of this interventional clinical trial is to evaluate the dose of radiation of Technetium-99m macroaggregated-albumin (99mTc-MAA) after an intra-arterial injection to the whole body and non-liver critical organs in…
- Conditions
- Carcinoma, Carcinoma, Hepatocellular, Liver Neoplasm
- Trial name
- MAApping (NCT05848947)
- Testing
- 99mTc-Macro Albumin Aggregate
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Sirtex Medical
Colorectal Cancer, Quality of Life
RESPONSE: Colorectal Cancer Survivors' Follow-up Care - Now Digital and Need-based
Over the last decades, the 3-year recurrence rates for patients with stage I and II colorectal cancer have decreased to just 5% and 12%.
- Conditions
- Colorectal Cancer, Quality of Life, Survivorship
- Trial name
- RESPONSE (NCT06614647)
- Testing
- Recurrence monitoring with circulating tumor DNA (ctDNA) as a high risk biomarker, Monitoring for late adverse effects with electronic patient reported outcome measures (ePROMs), Systematic treatment of organ-specific late effects and/or biopsychosocial late effects
- Where
- 9 sites in Denmark
- Volunteers
- 400 people
- Sponsor
- University of Aarhus